Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1999 2
2000 3
2012 1
2014 1
2015 1
2016 2
2017 4
2018 2
2019 6
2020 8
2021 15
2022 7
2023 7
2024 12
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, Popoli P, Ferraris L, Marrocco-Trischitta MM, Ripamonti D, Binda F, Bonfanti P, Squillace N, Castelli F, Muiesan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolongo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Botti G, Cardone C, Gargiulo P, Gravina A, Schettino C, Arenare L, Chiodini P, Gallo C; TOCIVID-19 investigators, Italy. Perrone F, et al. Among authors: arenare l. J Transl Med. 2021 Oct 21;19(1):442. doi: 10.1186/s12967-021-03094-9. J Transl Med. 2021. PMID: 34674735 Free PMC article. No abstract available.
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, Popoli P, Ferraris L, Marrocco-Trischitta MM, Ripamonti D, Binda F, Bonfanti P, Squillace N, Castelli F, Muiesan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolongo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Botti G, Cardone C, Gargiulo P, Gravina A, Schettino C, Arenare L, Chiodini P, Gallo C; TOCIVID-19 investigators, Italy. Perrone F, et al. Among authors: arenare l. J Transl Med. 2020 Oct 21;18(1):405. doi: 10.1186/s12967-020-02573-9. J Transl Med. 2020. PMID: 33087150 Free PMC article. Clinical Trial.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Among authors: arenare l. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.
Pignata S, Califano D, Lorusso D, Arenare L, Bartoletti M, De Giorgi U, Andreetta C, Pisano C, Scambia G, Lombardi D, Farolfi A, Cinieri S, Passarelli A, Salutari V, De Angelis C, Mignogna C, Priolo D, Capoluongo ED, Tamberi S, Scaglione GL, Arcangeli V, De Cecio R, Scognamiglio G, Greco F, Spina A, Turinetto M, Russo D, Carbone V, Casartelli C, Schettino C, Perrone F. Pignata S, et al. Among authors: arenare l. Ann Oncol. 2024 Jul;35(7):667-676. doi: 10.1016/j.annonc.2024.04.007. Epub 2024 May 3. Ann Oncol. 2024. PMID: 38704093 Free article. Clinical Trial.
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
Roma C, Esposito Abate R, Sacco A, Califano D, Arenare L, Bergantino F, Pisano C, Cecere SC, Scambia G, Lorusso D, Artioli G, Tasca G, Spina A, Russo D, Gadducci A, De Angelis C, Bologna A, Marchini S, Capoluongo ED, Perrone F, Pignata S, Normanno N. Roma C, et al. Among authors: arenare l. Eur J Cancer. 2024 Jul;206:114127. doi: 10.1016/j.ejca.2024.114127. Epub 2024 May 23. Eur J Cancer. 2024. PMID: 38797038
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.
Bignotti E, Simeon V, Ardighieri L, Kuhn E, Marchini S, Califano D, Cecere SC, Bugatti M, Spina A, Scognamiglio G, Paracchini L, Russo D, Arenare L, Tognon G, Lorusso D, Beltrame L, D'Incalci M, Sartori E, De Censi A, Odicino F, Perrone F, Chiodini P, Pignata S. Bignotti E, et al. Among authors: arenare l. Int J Cancer. 2025 Mar 1;156(5):1085-1096. doi: 10.1002/ijc.35203. Epub 2024 Oct 16. Int J Cancer. 2025. PMID: 39415516 Free PMC article.
Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial.
Indraccolo S, Signoriello S, Piga I, Esposito G, Ferrarini F, Boscolo Bragadin A, Salutari V, Pisano C, Califano D, Bignotti E, Tognon G, Simeon V, Artioli G, Ferrero A, Cinieri S, Bologna A, Chiodini P, Scognamiglio G, Bottoni C, Spina A, Russo D, Arenare L, Perrone F, Pignata S. Indraccolo S, et al. Among authors: arenare l. Int J Biol Markers. 2024 Dec;39(4):328-337. doi: 10.1177/03936155241296164. Epub 2024 Nov 8. Int J Biol Markers. 2024. PMID: 39513196 Free article.
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients.
Gravina A, Gargiulo P, De Laurentiis M, Arenare L, De Placido S, Orditura M, Cinieri S, Riccardi F, Ribecco AS, Putzu C, Del Mastro L, Rossi E, Ciardiello F, Di Rella F, Nuzzo F, Pacilio C, Caputo R, Cianniello D, Forestieri V, Giuliano M, Arpino G, Orlando L, Mocerino C, Schettino C, Piccirillo MC, Gallo C, Perrone F. Gravina A, et al. Among authors: arenare l. ESMO Open. 2025 Jan;10(1):104085. doi: 10.1016/j.esmoop.2024.104085. Epub 2025 Jan 3. ESMO Open. 2025. PMID: 39754976 Free PMC article. Clinical Trial.
Programmed death-ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV-2 translational study.
Basso-Valentina F, Canzonieri V, De Cecio R, Arenare L, Lorusso D, Cecere SC, Pivetta E, Russo D, Di Mauro A, Artioli G, Spina A, De Angelis C, Califano D, Cinieri S, Scognamiglio G, Salutari V, Chiodini P, Perrone F, Pignata S, Baldassarre G. Basso-Valentina F, et al. Among authors: arenare l. Clin Transl Med. 2025 Jun;15(6):e70373. doi: 10.1002/ctm2.70373. Clin Transl Med. 2025. PMID: 40545725 Free PMC article. No abstract available.
73 results